SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has announced the initiation of a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The program is aligned with U.S. Food and Drug Administration (FDA) requirements and is intended to support an Investigational New Drug (IND) application, a necessary step before first-in-human clinical trials.
The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, with preclinical results positioning GEP-44 head-to-head with established leaders such as Ozempic, Mounjaro, and Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes.
SureNano is positioning itself as an agile entrant in the next-generation GLP-1 landscape, having secured licensing rights to the GEP-44 compound developed by Syracuse University. The company’s transition toward a pharmaceutical-focused model follows its acquisition of GlucaPharm, now operating in the rapidly expanding GLP market.
The global GLP-1 receptor agonist market is substantial, with projections ranging from $100 billion to J.P. Morgan estimates of the broader incretin market reaching $200 billion by 2030. In the United States alone, approximately 25 million patients are expected to use GLP-1 therapies by 2030. SureNano aims to capture a share of this market with its patented second-generation incretin-based therapy.
In addition to its obesity and diabetes pipeline, the company is also exploring acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments. This diversification could open additional revenue streams and address significant unmet medical needs.
The news is important for industry leaders and investors as it signals SureNano’s advancement toward clinical-stage development in a high-growth therapeutic area. The GLP-1 market is dominated by pharmaceutical giants, and SureNano’s progress with GEP-44 could offer a competitive alternative if clinical trials prove successful. The company’s ability to navigate regulatory pathways and secure funding will be critical.
For more information, visit the company’s newsroom at https://ibn.fm/SURNF.
